Skip to main content
main-content

20-02-2022 | ASCO GU 2022 | Conference coverage | Video

Olaparib plus abiraterone could be a new first-line treatment option for mCRPC

share
SHARE

Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps (3:41).

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.